VF
FRTX

Virtu Financial’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Virtu Financial’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-43,558
Closed -$42K – 2202
2023
Q3 		$42K Buy
43,558
+30,716
+239% +$21.7K ﹤0.01% 927
2023
Q2 		$9K Sell
12,842
-17,458
-58% -$10.6K ﹤0.01% 1368
2023
Q1 		$20K Buy
+30,300
New +$50.6K ﹤0.01% 1248
2022
Q1 		– Sell
-4,916
Closed -$51K – 2255
2021
Q4 		$51K Buy
+4,916
New +$88.3K 0.01% 1337
2021
Q2 		– Sell
-1,458
Closed -$72K – 2223
2021
Q1 		$72K Buy
1,458
+1,032
+242% +$56.7K 0.01% 1385
2020
Q4 		$15K Buy
+426
New +$13.4K ﹤0.01% 1374
2019
Q2 		– Sell
-386
Closed -$146K – 1969
2019
Q1 		$146K Buy
+386
New +$129K 0.01% 1069
2018
Q4 		– Sell
-96
Closed -$41K – 2084
2018
Q3 		$41K Buy
96
+52
+118% +$21.9K ﹤0.01% 1325
2018
Q2 		$16K Sell
44
-84
-66% -$39.6K ﹤0.01% 1879
2018
Q1 		$59K Buy
+128
New +$63.6K ﹤0.01% 1680

Other funds holding FRTX

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Virtu Financial's FRTX Position: Q4 2023 in Review

Virtu Financial sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2023, closing a stake of 43,558 shares — an estimated $42K sold.

Virtu Financial first reported a position in FRTX in Q1 2018 and held it in 10 quarters. The position peaked at $146K in Q1 2019. 1 fund tracked by Wall St. Rank holds FRTX as of Q4 2023.

  • Virtu Financial reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Virtu Financial sold 43,558 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $42K.
  • Virtu Financial first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2018 and held it in 10 quarters.
  • Virtu Financial's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $146K in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.